Skip to content

New Partnerships; Samsung Adalimumab Updates; Part 3 Ustekinumab Outcomes

Alteogen and Alvotech announce updates for his or her respective license partnerships; Samsung Bioepis hurries up interchangeability research for its adalimumab biosimilar; Dong-A ST shares optimistic part 3 outcomes for its ustekinumab biosimilar.

New Licensing Agreements for Alteogen, Alvotech

Daejeon, Republic of Korea–based mostly Alteogen entered into an unique license settlement with Sandoz to develop and commercialize a subcutaneous model of a Sandoz biosimilar merchandise utilizing Alteogen’s Hybrozyme Know-how. The settlement additionally consists of an choice to license the expertise for two additional merchandise.

Alteogen will obtain upfront funds and milestone funds as Sandoz meets specified growth, regulatory, and gross sales milestones. Alteogen may even obtain tiered royalty funds for gross sales of the commercialized product. The merchandise included within the deal weren’t publicly disclosed.

Moreover, Alvotech expanded its partnership with Fuji Pharma, granting the latter the commercialization rights to an undisclosed biosimilar candidate in Japan. The businesses have been in an unique partnership settlement since November 2018.

Samsung Bioepis Gives Updates on Adalimumab Biosimilar

Samsung Bioepis disclosed that it obtained home product licensing for its adalimumab biosimilar referencing Humira within the Republic of Korea, based on Korea Biomedical Evaluation. The biosimilar was authorized as a prefilled syringe (40 mg/0.4 mL) and an auto-injector pen (40 mg/0.4 mL) and might be marketed beneath the identify Adallocé. The product is a high-concentration, citrate-free formulation.

Adalloce might be used to deal with sufferers with rheumatoid arthritis, psoriatic arthritis, axial spinal arthritis, Crohn illness, psoriasis, ulcerative colitis, Becchett enteritis, purulent hives, and nephritis in adults, and Crohn illness, idiopathic arthritis, and plate dryness in pediatric sufferers .

As well as, the Korea Herald reported that Samsung Bioepis is dashing up the processes for acquiring an interchangeability designation for Adallocé in the US, the place will probably be marketed as Hadlima when it enters the US market in July 2023.

The corporate initially deliberate to finish the research wanted to acquire the designation by September 2023. Nevertheless, it is going to now intention to complete the research in Could 2023. When Hadlima launches, the biosimilar won’t have an interchangeable label and will probably be marketed by Samsung Bioepis’ US licensing companion Organon.

Dong-A ST Shares Part 3 Ustekinumab Outcomes

Dong-A ST, an organization based mostly within the Republic of Korea, introduced {that a} part 3 therapeutic equivalence research demonstrated that the corporate’s ustekinumab biosimilar (DMB-3115) has comparable security and efficacy profiles to the reference product (Stelara), based on a report from Korea Biomedical Evaluation.

Ustekinumab merchandise are used to deal with inflammatory illnesses, together with Crohn’s illness, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. Stelara is without doubt one of the highest-grossing organic medicine on the earth, accumulating $16.8 billion in international gross sales throughout the third quarter of 2022.

The part 3 research performed in 2021 in the US and 9 different international locations, reminiscent of Poland, Estonia, and Latvia. The research included 605 individuals with reasonable to extreme continual plaque psoriasis and evaluated the protection, efficacy, and immunogenicity of DMB-3115 over 52 weeks.

DMB-3115 has been collectively developed by Dong-A Socio Holding and Meiji Seika Pharma since 2013. Dong-A ST obtained the commercialization and growth rights to the biosimilar in July 2020.


Leave a Reply

Your email address will not be published. Required fields are marked *